BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31841758)

  • 1. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
    Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
    Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Stenström J; Hedenfalk I; Hagerling C
    Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
    Yoshida K; Okamoto M; Sasaki J; Kuroda C; Ishida H; Ueda K; Ideta H; Kamanaka T; Sobajima A; Takizawa T; Tanaka M; Aoki K; Uemura T; Kato H; Haniu H; Saito N
    BMC Cancer; 2020 Jan; 20(1):25. PubMed ID: 31914969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells.
    Cai B; Ma P; Ding P; Sun DW; Bu Q; Zhang J
    APMIS; 2020 Mar; 128(3):260-269. PubMed ID: 31811667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
    Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
    Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
    Wang R; Feng W; Wang H; Wang L; Yang X; Yang F; Zhang Y; Liu X; Zhang D; Ren Q; Feng X; Zheng G
    Cancer Lett; 2020 Jan; 469():151-161. PubMed ID: 31669202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
    Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
    Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
    Toor SM; Syed Khaja AS; Alkurd I; Elkord E
    Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
    Hatzioannou A; Boumpas A; Papadopoulou M; Papafragkos I; Varveri A; Alissafi T; Verginis P
    Front Immunol; 2021; 12():731947. PubMed ID: 34539668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
    Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
    Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    Kuehnemuth B; Piseddu I; Wiedemann GM; Lauseker M; Kuhn C; Hofmann S; Schmoeckel E; Endres S; Mayr D; Jeschke U; Anz D
    BMC Cancer; 2018 Dec; 18(1):1278. PubMed ID: 30572845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.
    Luo CT; Liao W; Dadi S; Toure A; Li MO
    Nature; 2016 Jan; 529(7587):532-6. PubMed ID: 26789248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
    Hossain DM; Panda AK; Chakrabarty S; Bhattacharjee P; Kajal K; Mohanty S; Sarkar I; Sarkar DK; Kar SK; Sa G
    Immunology; 2015 Apr; 144(4):561-73. PubMed ID: 25284464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
    Saito T; Nishikawa H; Wada H; Nagano Y; Sugiyama D; Atarashi K; Maeda Y; Hamaguchi M; Ohkura N; Sato E; Nagase H; Nishimura J; Yamamoto H; Takiguchi S; Tanoue T; Suda W; Morita H; Hattori M; Honda K; Mori M; Doki Y; Sakaguchi S
    Nat Med; 2016 Jun; 22(6):679-84. PubMed ID: 27111280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
    Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.